The antifolate activity and the transport characteristics of isoaminopterin (IA) 
The antifolate activity and the transport characteristics of isoaminopterin (IA) in HeLa cells were studied and compared with those of methotrexate (MTX). Both IA and MTX inhibited the incorporation of [2-'4C]deoxyuridine into HeLa cell DNA by 50% at a concentration of 0.09 LM by 8 h postaddition of the compounds. Unlike MTX, the inhibition of DNA synthesis by IA was time dependent and reached a maximum at 24 h. IA-induced inhibition was due to interference with folate metabolism, since it could be completely reversed with N5-formyl-tetrahydrofolate. Competitive transport experiments between IA and either radiolabeled MTX or radiolabeled folate showed that IA preferentially uses the reduced folate/MTX transport system. IA inhibited MTX uptake by 50% at a concentration of 6.8 ,uM but had a negligible effect on folate transport.
The use of aminopterin and methotrexate (MTX) in the treatment of neoplastic diseases is well known (1, 2, 4, 13, 14, 16) . MTX is used either alone or in combination with other drugs for the treatment of leukemia (1, 14), Burkitt's lymphoma (2) , choriocarcinoma (13) , and psoriasis (16) , as well as for the suppression of the immune response (4, 15) . In spite of a documented high level of toxicity and the development of resistance (6) , MTX continues to be one of the most widely used anticancer drugs.
As part of a continuing program aimed at developing less toxic and more specific antifolate drugs for the treatment of different forms of cancer, we have synthesized a number of classical analogs of folic acid and aminopterin which are altered in the C9-N10 bridge region (7) (8) (9) (10) (11) . One of these compounds, isoaminopterin (IA; N-[p-{ ((2,4-diamino-4-deoxy-6-pteridinyl)amino) methyl} -benzoyl]-L-glutamic acid) (11), has been evaluated for anticancer activity in L1210 leukemic mice at The National Cancer Institute, National Institutes of Health, as described by Geran et al. (3) . At the maximum dose tested (4.0 mg/kg), IA showed significant activity (% T/C 2125/s42) against L1210 leukemia in mice.
In vitro studies with IA indicate that it is a very powerful antifolate. Nair et al. (11) have shown that it inhibits the growth of two folate-requiring organisms, Lactobacillus casei (ATCC 7469) and Streptococcus faecium (ATCC 8043) , and is an effective inhibitor of dichloromethotrexateresistant L. casei dihydrofolate reductase.
In this study the antifolate activity of IA is evaluated in a mammalian cell line in relation to (i) its ability to inhibit the incorporation of [2- '4C]deoxyuridine into DNA, (ii) the effect of N5- '4C]deoxyuridine (0.025 ,uCi/ml) at 37°C for 2.5 h at specific time intervals after addition of IA or MTX. At the end of each respective incubation period, the cultures were washed with ice-cold phosphatebuffered NaCI, harvested, and pelleted. The cells were suspended in 2.5 ml of distilled water. The DNA was precipitated with 0.25 N perchloric acid and collected on 0.45-,um Millipore membrane filters. The acid-precipitable counts were determined by liquid scintillation spectrophotometry. As control, the incorporation of radiolabel in untreated cells was determined. 
RESULTS
The effect of folate analogs on DNA synthesis was monitored by measuring the incorporation of radiolabeled deoxyuridine into acid-precipitable counts. The rate of incorporation of deoxyuridine into HeLa cell DNA as a function of time was determined by incubating semiconfluent monolayers of cells in the presence of [2-w4C] deoxyubrdine for varying periods of time.
At the end of the incubation period, the cultures were harvested, and the acid-precipitable radioactivity incorporated into DNA was determined.
As shown in Fig. 2 into acid-precipitable counts by 88% at a concentration of 5 ,uM (Fig. 3A) , whereas IA only produced a 45% inhibition at this concentration (Fig. 3B) . However, at 24 h, MTX and IA were comparably effective in inhibiting DNA synthesis. The 50% inhibitory dose values for MTX and IA were 0.08 ,uM and 0.05 ,tM, respectively (Fig. 3) . From these results it is apparent that IA is as effective as MTX in inhibiting HeLa cell DNA synthesis at 24 h postaddition of the compounds, and that IA is a slower-acting compound. deoxyuridine at 33 h postaddition of the compounds. As controls, parallel cultures were incubated under the same experimental conditions in the absence of N5-formyl-THF. As shown in Fig. 4 , the inhibition of DNA synthesis induced by both IA and MTX was completely reversed by N5-formyl-THF at a concentration of 1.0 1iM. These results indicate that IA-induced inhibition of HeLa cell DNA synthesis is due to interference with folate metabolism.
HeLa cells have different transport systems for MTX and folic acid (12) . Competitive transport experiments between IA and either radiolabeled MTX or radiolabeled folate were performed to determine the transport pathway (5, 12) . The cultures were harvested, and the amount of radioactivity associated with the cells was determined. As shown in Fig. 5 (12) . In the present study, IA inhibited the transport of MTX by 50% at a concentration of 6.8 jiM (Fig.  5) . These data suggest that MTX and 10-oxaaminopterin are transported into HeLa cells with a greater affinity than IA and 10-thioaminopterin, and IA is transported into the cell with the least affinity.
Dihydrofolate reductase converts dihydrofolate to tetrahydrofolate. The latter is a coenzyme in various one-carbon transfer reactions. Like MTX, IA is a powerful inhibitor of this enzyme (11) . The 50% inhibitory dose of MTX for dichloromethotrexate-resistant L. casei dihydrofolate reductase is approximately two times less than that of IA (11) . Further studies are required to determine the factor(s) responsible for the time-dependent effect of IA on host-cell DNA synthesis. Whether or not the combined attributes of high antifolate activity and time dependency exhibited by IA will result in decreased toxicity and increased therapeutic index compared to MTX must await further in vivo anticancer evaluation. 
